One-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and a favorable safety ...

Envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor, demonstrated rapid improvement and progressively deepening skin ...

HealthDay News — Once-daily oral zasocitinib (TAK-279), an oral tyrosine kinase 2 (TYK2) inhibitor, provides a durable response in adults with moderate-to-severe plaque psoriasis (PsO), according to a ...

Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) has approved ICOTYDE™ (icotrokinra), an interleukin-23 (IL-23) receptor antagonist for the treatment of ...

84% of adolescents with moderate-to-severe plaque psoriasis treated with investigational icotrokinra achieved clear or almost clear skin (IGA 0/1) at Week 16 ICONIC-LEAD is the first ever Phase 3 ...

Patients initially on placebo who switched to Icotyde at week 16 showed comparable clearance by week 52.

That trade-off may soon change. New clinical trial data suggests a once-daily pill called zasocitinib may provide the clear ...

Otezla is the first oral therapy approved for moderate to severe plaque psoriasis in this patient population. The Food and Drug Administration (FDA) has expanded the approval of Otezla ® (apremilast) ...

Several classification systems, all based on disease severity, have been created to guide treatment decisions in psoriasis. In the most widely used system, disease severity is scored according to the ...

Eli Lilly and Company (NYSE: LLY) announced today that patients with moderate-to-severe plaque psoriasis who did not respond to treatment with etanercept achieved significant improvement in their ...

Although some people with plaque psoriasis can control their symptoms by using topical treatments that are applied to the skin, some people with moderate or severe plaque psoriasis do not get enough ...

ICONIC-LEAD is the first ever Phase 3 registrational study in moderate-to-severe plaque psoriasis to assess safety and efficacy of a systemic therapy in adolescents and adults simultaneously 84% of ...